Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
European Journal of Cancer2019Vol. 109, pp. 36–50
Citations Over TimeTop 1% of 2019 papers
Sigbjørn Smeland, Stefan Bielack, Jeremy Whelan, Mark L. Bernstein, Pancras C.W. Hogendoorn, Mark Krailo, Richard Görlick, Katherine A. Janeway, Fiona C. Ingleby, Jakob Anninga, Imre Antal, Carola Arndt, Ken Brown, Trude Butterfaß‐Bahloul, Gabriele Calaminus, Michael Capra, Catharina Dhooge, Mikael Eriksson, Adrienne M. Flanagan, Godehard Friedel, Mark C. Gebhardt, Hans Gelderblom, Robert E. Goldsby, Holcombe E. Grier, R. J. Grimer, Douglas S. Hawkins, Stefanie Hecker‐Nolting, Kirsten Sundby Hall, Michael S. Isakoff, Gordana Jovic, Thomas Kühne, Leo Kager, Thekla von Kalle, Edita Kabíčková, Susanna Lang, Ching C. Lau, Patrick J. Leavey, Stephen L. Lessnick, Leo Mascarenhas, Regine Mayer‐Steinacker, Paul A. Meyers, Raj Nagarajan, R. Lor Randall, Peter Reichardt, Marleen Renard, Catherine Rechnitzer, Cindy L. Schwartz, Sandra J. Strauss, Lisa A. Teot, Beate Timmermann, Matthew R. Sydes, Neyssa Marina
Abstract
In conclusion, data from >2000 patients registered to EURAMOS-1 demonstrated survival rates in concordance with institution- or group-level osteosarcoma trials. Further efforts are required to drive improvements for patients who can be identified to be at higher risk of adverse outcome. This trial reaffirms known prognostic factors, and owing to the large numbers of patients registered, it sheds light on some additional factors to consider.
Related Papers
- Correlation Between ErbB2 Expression and Survival Rates of Osteosarcoma Patients(2014)
- → Is Treatment Response Prognostic in Non–Small-Cell Lung Cancer?(2015)
- → Diaphyseal osteosarcoma or synchronous osteosarcoma(2020)
- → Figure S3 from Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial)(2023)
- → Figure S3 from Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial)(2023)